Drug Formulation Market Size To Cross USD 2.95 Trn By 2032

The global drug formulation market size accounted for US$ 1.64 Trn in 2022 and is projected to reach around USD 2.95 Trn by 2032, growing at a CAGR of 6.05% from 2023 to 2032.

Report Summary

The global drug formulation market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the drug formulation market across the globe.

A comprehensive estimate on the drug formulation market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of drug formulation during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2561

Drug Formulation Market Report Scope 

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized drug formulation market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read:  Humanoid Robot Market Size To Cross USD 28.66 Bn By 2032

Drug Formulation Market Players

The report includes the profiles of key drug formulation market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Major companies operating in this area

• Bristol-Myers Squibb
• Eli Lilly and Company
• Gilead Sciences, Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• F. Hoffmann-La Roche AG
• Johnson & Johnson
• 3M Company
• Bayer AG
• Teva Pharmaceuticals Industries Ltd.
• Amgen, Inc.
• Sanofi SA
• GlaxoSmithKline plc
• Boston

Market Segmentation

By Formulation

• Tablets
• Capsules
• Injectable
• Sprays
• Suspensions
• Powders
• Other Formulations

By Routes of Administration

• Oral
• Topical
• Parenteral
• Inhalations
• Other Routes of Administration

By Therapy Area

• Cardiovascular Diseases (CVDs)
• Pain
• Diabetes
• Cancer
• Respiratory Diseases
• Other Diseases

By End-User

• Retail
• Non-retail

Regional Segmentation

• North America (U.S., Canada, Mexico)
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
• Latin America (Brazil and Rest of Latin America)
• Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

• Governmental bodies, and organizations creating economic policies
• National and international social welfare institutions
• Company websites, financial reports and SEC filings, broker and investor reports
• Related patent and regulatory databases
• Statistical databases and market reports
• Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

• Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
• In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Drug Formulation Market 

5.1. COVID-19 Landscape: Drug Formulation Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Drug Formulation Market, By Formulation

8.1. Drug Formulation Market, by Formulation, 2023-2032

8.1.1. Tablets

8.1.1.1. Market Revenue and Forecast (2023-2032)

8.1.2. Capsules

8.1.2.1. Market Revenue and Forecast (2023-2032)

8.1.3. Injectable

8.1.3.1. Market Revenue and Forecast (2023-2032)

8.1.4. Sprays

8.1.4.1. Market Revenue and Forecast (2023-2032)

8.1.5. Suspensions

8.1.5.1. Market Revenue and Forecast (2023-2032)

8.1.6. Powders

8.1.6.1. Market Revenue and Forecast (2023-2032)

8.1.7. Other Formulations

8.1.7.1. Market Revenue and Forecast (2023-2032)

Chapter 9. Global Drug Formulation Market, By Routes of Administration

9.1. Drug Formulation Market, by Routes of Administration, 2023-2032

9.1.1. Oral

9.1.1.1. Market Revenue and Forecast (2023-2032)

9.1.2. Topical

9.1.2.1. Market Revenue and Forecast (2023-2032)

9.1.3. Parenteral

9.1.3.1. Market Revenue and Forecast (2023-2032)

9.1.4. Inhalations

9.1.4.1. Market Revenue and Forecast (2023-2032)

9.1.5. Other Routes of Administration

9.1.5.1. Market Revenue and Forecast (2023-2032)

Chapter 10. Global Drug Formulation Market, By Therapy Area 

10.1. Drug Formulation Market, by Therapy Area, 2023-2032

10.1.1. Cardiovascular Diseases (CVDs)

10.1.1.1. Market Revenue and Forecast (2023-2032)

10.1.2. Pain

10.1.2.1. Market Revenue and Forecast (2023-2032)

10.1.3. Diabetes

10.1.3.1. Market Revenue and Forecast (2023-2032)

10.1.4. Cancer

10.1.4.1. Market Revenue and Forecast (2023-2032)

10.1.5. Respiratory Diseases

10.1.5.1. Market Revenue and Forecast (2023-2032)

10.1.6. Other Diseases

10.1.6.1. Market Revenue and Forecast (2023-2032)

Chapter 11. Global Drug Formulation Market, By End-User 

11.1. Drug Formulation Market, by End-User, 2023-2032

11.1.1. Retail

11.1.1.1. Market Revenue and Forecast (2023-2032)

11.1.2. Non-retail

11.1.2.1. Market Revenue and Forecast (2023-2032)

Chapter 12. Global Drug Formulation Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.1.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.1.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.1.4. Market Revenue and Forecast, by End-User (2023-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.1.5.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.1.5.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.1.5.4. Market Revenue and Forecast, by End-User (2023-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.1.6.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.1.6.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.1.6.4. Market Revenue and Forecast, by End-User (2023-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.2.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.2.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.2.4. Market Revenue and Forecast, by End-User (2023-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.2.5.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.2.5.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.2.5.4. Market Revenue and Forecast, by End-User (2023-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.2.6.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.2.6.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.2.6.4. Market Revenue and Forecast, by End-User (2023-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.2.7.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.2.7.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.2.7.4. Market Revenue and Forecast, by End-User (2023-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.2.8.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.2.8.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.2.8.4. Market Revenue and Forecast, by End-User (2023-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.3.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.3.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.3.4. Market Revenue and Forecast, by End-User (2023-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.3.5.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.3.5.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.3.5.4. Market Revenue and Forecast, by End-User (2023-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.3.6.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.3.6.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.3.6.4. Market Revenue and Forecast, by End-User (2023-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.3.7.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.3.7.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.3.7.4. Market Revenue and Forecast, by End-User (2023-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.3.8.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.3.8.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.3.8.4. Market Revenue and Forecast, by End-User (2023-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.4.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.4.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.4.4. Market Revenue and Forecast, by End-User (2023-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.4.5.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.4.5.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.4.5.4. Market Revenue and Forecast, by End-User (2023-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.4.6.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.4.6.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.4.6.4. Market Revenue and Forecast, by End-User (2023-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.4.7.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.4.7.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.4.7.4. Market Revenue and Forecast, by End-User (2023-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.4.8.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.4.8.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.4.8.4. Market Revenue and Forecast, by End-User (2023-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.5.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.5.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.5.4. Market Revenue and Forecast, by End-User (2023-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.5.5.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.5.5.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.5.5.4. Market Revenue and Forecast, by End-User (2023-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Formulation (2023-2032)

12.5.6.2. Market Revenue and Forecast, by Routes of Administration (2023-2032)

12.5.6.3. Market Revenue and Forecast, by Therapy Area (2023-2032)

12.5.6.4. Market Revenue and Forecast, by End-User (2023-2032)

Chapter 13. Company Profiles

13.1. Bristol-Myers Squibb

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Eli Lilly and Company

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Gilead Sciences, Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Merck & Co., Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Novartis AG

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Pfizer Inc.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. AbbVie Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Boehringer Ingelheim International GmbH

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. F. Hoffmann-La Roche AG

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Johnson & Johnson

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com